三星医疗
(601567)
| 流通市值：465.38亿 | | | 总市值：468.06亿 |
| 流通股本：14.03亿 | | | 总股本：14.11亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 10,433,714,281.29 | 6,997,465,533.74 | 3,024,788,914.34 | 11,462,508,357.39 |
| 营业收入 | 10,433,714,281.29 | 6,997,465,533.74 | 3,024,788,914.34 | 11,462,508,357.39 |
| 二、营业总成本 | 8,580,662,700.55 | 5,848,534,696.67 | 2,639,988,293.38 | 9,763,004,868.05 |
| 营业成本 | 6,655,350,057.66 | 4,575,564,451.09 | 2,080,948,349.73 | 7,566,256,973.36 |
| 税金及附加 | 66,979,224.48 | 42,612,901.31 | 17,187,151.85 | 83,514,151.5 |
| 销售费用 | 708,649,087.89 | 488,593,822.5 | 225,615,769.63 | 850,512,800.32 |
| 管理费用 | 658,677,578.27 | 410,117,379.28 | 190,159,289.28 | 800,732,091.73 |
| 研发费用 | 413,019,007.29 | 277,566,342.29 | 107,606,619.48 | 470,826,747.37 |
| 财务费用 | 77,987,744.96 | 54,079,800.2 | 18,471,113.41 | -8,837,896.23 |
| 其中:利息费用 | 73,174,347.78 | 53,059,895.79 | 22,237,676.51 | 52,751,297.12 |
| 其中:利息收入 | 55,838,778.46 | 51,589,604.25 | 26,693,136.76 | 46,438,687.31 |
| 加:公允价值变动收益 | -76,740,042.89 | -49,957,542.6 | -43,237,403.34 | 116,974,985 |
| 加:投资收益 | 177,637,485.16 | 128,573,815.19 | 63,420,212.59 | 296,136,980.39 |
| 资产处置收益 | -248,929.17 | 190,888.03 | 90,158.95 | -98,954.19 |
| 资产减值损失(新) | -29,658,832.7 | -14,588,801.01 | -7,489,371.32 | -12,987,056.48 |
| 信用减值损失(新) | -23,622,575.74 | -10,880,217.42 | 1,182,516.67 | -11,638,995.15 |
| 其他收益 | 176,224,563.02 | 113,234,330.54 | 34,019,810.52 | 182,561,062.58 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 2,076,643,248.42 | 1,315,503,309.8 | 432,786,545.03 | 2,270,451,511.49 |
| 加:营业外收入 | 61,930,639.73 | 56,996,236.55 | 3,494,294.92 | 12,181,286.43 |
| 减:营业外支出 | 20,866,731.81 | 13,855,912.76 | 1,062,304.57 | 20,565,673.49 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 2,117,707,156.34 | 1,358,643,633.59 | 435,218,535.38 | 2,262,067,124.43 |
| 减:所得税费用 | 294,927,746.69 | 204,546,725.11 | 70,875,288.62 | 341,263,185.97 |
| 六、净利润 | 1,822,779,409.65 | 1,154,096,908.48 | 364,343,246.76 | 1,920,803,938.46 |
| 持续经营净利润 | 1,822,779,409.65 | 1,154,096,908.48 | 364,343,246.76 | 1,920,803,938.46 |
| 归属于母公司股东的净利润 | 1,815,696,160.26 | 1,150,008,819.85 | 364,254,826.35 | 1,903,702,022.52 |
| 少数股东损益 | 7,083,249.39 | 4,088,088.62 | 88,420.41 | 17,101,915.94 |
| (一)基本每股收益 | 1.29 | 0.81 | 0.26 | 1.35 |
| (二)稀释每股收益 | 1.29 | 0.81 | 0.26 | 1.35 |
| 八、其他综合收益 | 1,812,403.58 | 10,108,329.32 | 231,698.54 | 32,154,968.92 |
| 归属于母公司股东的其他综合收益 | -7,082,179.12 | 11,773,004.66 | 233,665.37 | 30,111,472.81 |
| 九、综合收益总额 | 1,824,591,813.23 | 1,164,205,237.8 | 364,574,945.3 | 1,952,958,907.38 |
| 归属于母公司股东的综合收益总额 | 1,808,613,981.14 | 1,161,781,824.51 | 364,488,491.72 | 1,933,813,495.33 |
| 归属于少数股东的综合收益总额 | 15,977,832.09 | 2,423,413.28 | 86,453.58 | 19,145,412.05 |
| 公告日期 | 2024-10-25 | 2024-08-23 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |